TABLE 2.
Studies' Design
| Study Data | Tracer Administration | Imaging Session 1 (Before Intervention) | Intervention | Imaging Session 2 (After Intervention) | |||||
|---|---|---|---|---|---|---|---|---|---|
| Author (Year) | No. Patients | Tracer | Activity, MBq | Cold Octreotide Before Imaging | Protocol (Uptake Time Awaited) | Delay Imaging 1 Imaging 2 | Octreotide Before Imaging 2 | Last Administration of Cold Octreotide Before Imaging 2 | Protocol (Uptake Time Awaited) |
| Dörr et al (1993)5 |
5 | [111In]pentetreotide | 105–237 | None or withdrawal >24 h | Planar (30 min, 4 h, 24 h) |
<28 d | Octreotide (600 μg/d, ongoing) |
<1 d | Planar (30 min, 4 h, 24 h) |
| Soresi et al (1997)6 |
12 | [111In]pentetreotide | 110–130 | None | Planar (5 h) | 7 d | Octreotide (600 μg/d, 7 d) | <1 d | Planar (5 h) |
| Janson et al (1999)7 |
8 | [111In]pentetreotide | 114–238 | None | Planar (19–24 h) | 10–13 mo | Lanreotide (6000–12,000 μg/d) | 3 d | Planar (19–24 h) |
| Rolleman et al (2007)8 |
10 | [111In]pentetreotide | 220 | None | Planar (24 h) | 50–397 d | Octreotide (200–300 μg/d or LAR 20–30 mg/28 d) | 4–21 d (LAR) | Planar (24 h) |
| Velikyan et al (2010)9 |
6 | [68Ga]DOTATOC | 15–80 | None | Dynamic + whole body (50 min) |
<1 d | Octreotide (50 μg, 250 or 500 μg, single dose) | 10 min | Dynamic + whole body (50 min) |
| Haug et al (2011)10 |
9 | [68Ga]DOTATATE | 200 | None | Whole body (60 min) | 13.8 wk | Octreotide LAR (20–50 mg/28 d) |
NA | Whole body (60 min) |
| Ayati et al (2017)11 |
30 | [68Ga]DOTATATE | 110–185 | None | Whole body (60 min) | 9.6 mo | Octreotide LAR (30–60 mg/28 d) |
25.1 +/− 14.8 d | Whole body (60 min) |
| Aalbersberg et al (2018)12 |
34 | [68Ga]DOTATATE | 100 | Yes, imaging performed the day before the next administration | Whole body (45 min) | 2 d | Lanreotide LAR (60–120 mg/3–4 wk) |
1 d | Whole body (45 min) |
| Cherk et al (2018)13 |
21 | [68Ga]DOTATATE | 85–307 | None | Whole body (35–88 min) |
2–12 mo | Unspecified LAR (/28 d) | 21–28 d | Whole body (60 min) |
| Gålne et al (2019)14 |
19 | [68Ga]DOTATATE | 2.5/kg | None | Whole body (60 min) | 202 d | Unspecified LAR (/21 or /28 d) |
Between 1 and 31 d | Whole body (60 min) |
| Jahn et al (2021)15 |
4 | [68Ga]DOTATOC | 167 | Yes, 7–27 d | Whole body (1 h) | 1–3.5 mo | Octreotide 400 μg (in addition to LAR treatment) |
15 min | Whole body (1 h, 4 h, 7 h) and dynamic studies in between |
| Lodge et al (2021)3 |
7 | [68Ga]DOTATOC | 185 | None | 8 Whole body (8–100 min) |
1–20 d | Octreotide (50 μg, single dose) |
10–15 min | 8 Whole body (8–100 min) |